trastuzumab,pertuzumab
roche
['bcsm', 'adaptive ']
phergain: noncomparative randomized adaptive phase ii study, stage i-iiia, her2+ this update: *3-year idfs in group b (hp +/- tchp) = 95.4%
*98.8% idfs and no distant met in pts who never received chemo (had pet response and pcr with hp alone). #bcsm #asco23 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.